Le Lézard
Classified in: Health
Subject: SVY

Anpac Bio Surpasses 50,000 Case Study Milestone



SACRAMENTO, Calif., Oct. 17, 2017 /PRNewswire/ -- Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week the company set a new, international record, processing and reporting over 50,000 cases worldwide of the company's proprietary, "Cancer Differentiation Analysis" (CDA) liquid biopsy tests.

International life sciences leader Anpac Bio-Medical Science Company has developed breakthrough, proprietary, "Cancer Differentiation Analysis" technology that effectively reinvents cancer screening and early detection. Anpac's proprietary CDA medical devices analyze simple, standard, non-invasive "Blood Biopsies" - resulting in measurably greater early cancer detection sensitivity and specificity, with no harmful side effects in patients. The proven results of 25,000 cases to date demonstrate CDA's research validity achieving an average sensitivity and specificity rate range of 75%-90% for ten different types of cancer -- often identifying the type and location of threatening, diseased cancer cells before they form into tumors. (PRNewsFoto/Anpac Bio-Medical Science Co.)

Described as "game changing" and receiving the, "Breakthrough Innovation Award", at World Nobel Prize Laureate Summit; and named, "Most Promising Cancer Screening Company", at the 2017 Global Precision Medicine Industry Awards, Anpac Bio's CDA technology effectively reinvents early cancer screening and detection. By analyzing simple, in vitro, liquid or "Blood Biopsies", and applying Anpac Bio's proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac Bio's CDA technology identifies cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer "false positives"; at a cost substantially lower than traditional testing; and generating results within minutes of sample submission.

Comprehensive research validity data from the 50,000+ cases processed to date indicate Anpac Bio's CDA diagnostics far exceed existing or competing technologies - revealing a sensitivity and specificity rate range of 75%-90% for over 26+ different types of cancer ? most at the disease's earliest stages.

The company has filed over 160 CDA-related patent applications worldwide ? 64+ issued currently; and maintains operations in six sites, employing over 100 people globally.

"Since our company launched in 2008, Anpac Bio has pioneered the 'liquid biopsy' space," states Dr. Yu. "Because our CDA devices have already been approved by international regulatory bodies, and our research has been published and presented before respected scientific organizations, such as the American Society of Clinical Oncology (ASCO) and the World Nobel Prize Laureate Summit, our CDA tests are in great demand right now. We've processed over 50,000 CDA tests for individuals; and organizations such as health systems, insurance companies, corporations, and educational institutions. We're very proud our CDA devices have advanced beyond the laboratory, and are processing real tests for real people. And we have dozens of testimonials from people saying our CDA tests detected their early-stage cancer and saved their lives. At this rate, we project to double our CDA cases worldwide and save many more lives in 2018!"

For more information about Anpac Bio please check: www.AnpacBio.com.

 

SOURCE Anpac Bio-Medical Science Company


These press releases may also interest you

at 22:46
Acacia Network today issued the following statement reflecting on Hurricane María:   One year ago this day, we discovered the best in us. We discovered solidarity, courage, love, commitment, and thousands of unsung heroes...

at 22:45
Innovent Biologics, Inc. (Innovent), a world-class China-based biopharmaceutical company that develops and commercializes high quality drugs, today presented clinical trial data from a phase Ib clinical trial (NCT02937116) that treated patients with...

at 22:30
Today Huntsman Cancer Foundation (HCF) announced that several individuals and business organizations have committed a total of $40 million to support a proposed major building expansion of Huntsman Cancer Institute (HCI) at the University of Utah (U...

at 21:22
Staff at the Alpha Genesis Primate Research Center in Yemassee, South Carolina prepared delicious "monkey treats" for their primate friends prior to the expected arrival of Hurricane Florence. The monkeys calmly went about their monkey business...

at 21:06
Purus Labs, Inc is recalling MyoWhey Chocolate Cookie Crunch, because it may contain undeclared milk and soy. This only effects products with Lot number PL: 0100518 Exp: 04/2020. People who have an allergy or severe sensitivity to milk and soy run...

at 20:50
"Canada has a strong record of supporting our athletes and the anti-doping movement. "Our Government is troubled with the decision of the World Anti-Doping Agency (WADA) Executive Committee today to reinstate the Russian Anti-Doping Agency (RUSADA)....




News published on 17 october 2017 at 07:30 and distributed by: